Publication | Closed Access

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

Mdm2 Antagonist Rg7112MedicinePharmacologyPathologyAnti-cancer AgentTumor SuppressorCancer TreatmentP53 PathwayOncologyCancer ResearchTumor BiologyDedifferentiated Liposarcoma